Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Shares Shorted: Short Interest Down 50.2% in October

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 82,052 shares, a decrease of 50.2% from the September 30th total of 164,782 shares. Based on an average daily volume of 94,563 shares, the short-interest ratio is currently 0.9 days. Currently, 1.3% of the company’s shares are sold short.

Analysts Set New Price Targets

A number of analysts recently commented on CELZ shares. Roth Capital restated a “buy” rating on shares of Creative Medical Technology in a research report on Thursday, August 20th. Wall Street Zen upgraded Creative Medical Technology from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Finally, Weiss Ratings lowered Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Creative Medical Technology Stock Down 3.4%

Shares of NASDAQ:CELZ traded down $0.02 during mid-day trading on Friday, reaching $0.66. 87,006 shares of the stock were exchanged, compared to its average volume of 100,397. The company has a market cap of $4.32 million, a P/E ratio of -0.32 and a beta of 2.06. Creative Medical Technology has a one year low of $0.62 and a one year high of $4.72. The stock’s 50 day simple moving average is $0.93 and its 200-day simple moving average is $1.57.

Creative Medical Technology (NASDAQ:CELZ) last released its earnings results on Friday, August 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Analysts anticipate that Creative Medical Technology will post -1.18 EPS for the current fiscal year.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited.

The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform.